E Fund Management (HK)’s Vertex Pharmaceuticals VRTX Stock Holding History

E Fund Management (HK)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$405K	Buy	907 +47	+5%	+$21.9K	0.18%	77
2025 Q4	$406K	Buy	860 +616	+252%	+$266K	0.14%	75
2025 Q3	$95.6K	Buy	244 +124	+103%	+$51.8K	0.06%	84
2025 Q2	$53.4K	Hold	120	–	–	0.05%	88
2025 Q1	$58K	Buy	120 +99	+471%	+$46.1K	0.05%	84
2024 Q4	$8K	Buy	21 +17	+425%	+$7.88K	0.01%	111
2024 Q3	$2K	Hold	4	–	–	﹤0.01%	110
2024 Q2	$2K	Buy	+4	New	+$1.74K	﹤0.01%	89
2022 Q4	–	Sell	-6,500	Closed	-$1.88M	–	31
2022 Q3	$1.88M	Buy	+6,500	New	+$1.87M	1.49%	17

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

E Fund Management (HK)'s VRTX Position: Q1 2026 in Review

E Fund Management (HK) increased its Vertex Pharmaceuticals (VRTX) stake by 5.5% in Q1 2026, buying an estimated $21.9K and bringing the position to 907 shares worth $405K. The position accounts for 0.18% of the portfolio, ranked #77.

E Fund Management (HK) first reported a position in VRTX in Q3 2022 and has held it in 9 quarters since. The position peaked at $1.88M in Q3 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

E Fund Management (HK) held 907 shares of Vertex Pharmaceuticals worth $405K as of Q1 2026.
E Fund Management (HK) bought 47 Vertex Pharmaceuticals shares in Q1 2026, an estimated $21.9K.
Vertex Pharmaceuticals made up 0.18% of E Fund Management (HK)'s portfolio in Q1 2026, its #77 holding.
E Fund Management (HK) first reported a position in Vertex Pharmaceuticals in Q3 2022 and has held it in 9 quarters since.
E Fund Management (HK)'s Vertex Pharmaceuticals position peaked at $1.88M in Q3 2022.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on E Fund Management (HK)'s 13F filing for Q1 2026, filed 8 Apr 2026.